reproxalap
ADX-102 Small Molecule Target: RASP
Aldeyra Therapeutics
Most recent annual filing: 2026-02-15
- ADX-246 IND filing2026ADX-246 IND filing, 2026, notable
- ADX-248 Ph2 start2H 2026ADX-248 Ph2 start, 2H 2026, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (7 active programs)
reproxalap
Small Molecule Target: RASP
methotrexate
ADX-2191ADX-248
Small Molecule Target: RASP
- Atopic Dermatitis
- Undisclosed indication
ADX-246
Small Molecule Target: RASP
Technology platforms
RASP Modulator Platform
Platform of small molecule reactive aldehyde species (RASP) modulators that covalently bind and deplete RASP, modulating multiple inflammatory protein systems simultaneously. Disease focus includes ocular inflammatory diseases (dry eye disease, allergic conjunctivitis, age-related macular degeneration), systemic immune-mediated diseases (atopic dermatitis, psoriasis, asthma), and rare retinal diseases.
Targets: RASP, reactive aldehyde species
RASP Platform for Immune-Mediated Diseases
Reactive aldehyde species (RASP) modulation platform targeting immune-mediated diseases; disease focus includes dry eye disease, allergic conjunctivitis, atopic dermatitis, Sjögren-Larsson syndrome, obesity/hypertriglyceridemia, moderate alcohol-associated hepatitis, and CNS/neuroinflammatory disease.
Platform for Rare Retinal Inflammatory Diseases
Platform focused on rare retinal inflammatory diseases; lead candidate ADX-2191 administered via intravitreal injection for primary vitreoretinal lymphoma and proliferative vitreoretinopathy.
Discontinued (2)
- ADX-629 — undisclosed · completed proof-of-concept testing; no longer in development aside from potential investigator-sponsored trials in Sjögren-Larsson Syndrome
- ADX-2191 — Proliferative Vitreoretinopathy · Company ceased development of the Helio Product Candidate for the treatment of proliferative vitreoretinopathy during year ended December 31, 2024
Biotech Distilled coverage (8)
- 2026-09-30 UPDATE: Aldeyra Therapeutics (ALDX) - Going Over the Division’s Head 🔒 Paid
- 2026-08-07 UPDATE: Aldeyra Therapeutics (ALDX) - The Floor Keeps Sinking 🔒 Paid
- 2026-07-15 UPDATE: Aldeyra Therapeutics (ALDX) - The FDA Punts, Aldeyra Escalates
- 2026-05-08 UPDATE: Aldeyra Therapeutics (ALDX) - The Cash Floor Just Got Lower 🔒 Paid
- 2026-05-02 UPDATE: Aldeyra Therapeutics (ALDX) - Reading the FDA’s Margin Notes 🔒 Paid
- 2026-03-21 UPDATE: Aldeyra Therapeutics (ALDX) - The Bottom Falls Out 🔒 Paid
- 2026-02-28 UPDATE: Aldeyra Therapeutics (ALDX) - The Final Countdown to PDUFA 🔒 Paid
- 2025-12-17 BONUS: Aldeyra Therapeutics (ALDX): Scientific Due Diligence for Reproxalap and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.